TriangleZanzalintinib (NCT07218666)
Zanzalintinib trial for Aggressive Variant Prostate Carcinoma (NCT07218666). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with metastatic, castration-resistant prostate cancer meeting aggressive-variant criteria, after progression on an androgen-receptor pathway inhibitor. Pure small-cell carcinoma is excluded.
The idea: daily oral zanzalintinib, 60 milligrams, blocks signaling proteins involved in cancer growth and blood-vessel formation. Medical or surgical hormone suppression continues. Researchers measure progression-free survival. Eligibility requires specified clinical, laboratory, or genetic features; a neuroendocrine marker alone is not required for everyone.
This phase 2 study plans 30 patients. Deepak Kilari leads at the Medical College of Wisconsin in Milwaukee, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.